Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Last trade$0.8228
Day change-$0.0058 (-0.70%)
Day range$0.811 – $0.996
Volume173,284
Market cap$14M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.84M
Price / earnings
—
Price / book
1.14×
Price / sales
5.92×
EV / sales
1.07×
EV / EBITDA
-0.23×
Profitability
Earnings per share
-$0.52
Return on assets
-59.7%
Return on equity
-71.57%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.03×
Quick ratio
6.03×
Cash ratio
4.68×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MRKR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$1.1M
$1.23M
$0
$0
$2.25M
$1.93M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$1.1M
$1.23M
$0
$0
$2.25M
$1.93M
Selling, general and administrative
$1.14M
$1.23M
$846.61K
$1.02M
$945.16K
$1.37M
$1.03M
$854.68K
Research and development
$1.48M
$2.84M
$2.14M
$2.35M
$4.18M
$3.14M
$5.09M
$3.47M
Total operating expenses
$2.62M
$4.07M
$2.99M
$3.37M
$5.12M
$4.96M
$6.11M
$4.33M
Operating income
-$2.62M
-$4.07M
-$1.88M
-$2.14M
-$5.12M
-$4.96M
-$3.86M
-$2.4M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$1.83M
-$3.18M
-$1.72M
-$2M
-$4.02M
-$4.45M
-$3.79M
-$2.31M
Income taxes
$0
$0
-$15.16K
$0
$0
$0
$49.95K
$0
Net income
-$1.83M
-$3.18M
-$1.7M
-$2M
-$4.02M
-$4.45M
-$3.84M
-$2.31M
Net income attributable to common shareholders
-$1.83M
-$3.18M
-$1.7M
-$2M
-$4.02M
-$4.45M
-$3.84M
-$2.31M
EBITDA
-$2.62M
-$4.07M
-$1.88M
-$2.14M
-$5.12M
-$4.5M
-$3.86M
-$2.4M
Basic earnings per share
-$0.09
-$0.16
-$0.09
-$0.12
-$0.29
-$0.40
-$0.42
-$0.26
Diluted earnings per share
-$0.09
-$0.16
-$0.09
-$0.12
-$0.29
-$0.40
-$0.42
-$0.26
Recent news
Company coverage with links to the original publishers.
Marker Therapeutics reported a Q3 loss of $0.10 per share, beating EPS estimates but missing revenue expectations with $1.29 million in quarterly revenue. The company has underperformed the market by 41.6% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Rigel Pharmaceuticals (RIGL) reported quarterly earnings of $0.65 per share, missing the consensus estimate of $0.87 per share, representing a -25.29% earnings surprise. However, the company exceeded revenue expectations with $80.89 million versus the estimate of $78.27 million. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Marker Therapeutics (MRKR) is expected to report a quarterly loss of $0.12 per share with revenues of $2.45 million.
Marker Therapeutics received a $2.6 million FDA Orphan Products Clinical Trials grant to support Phase 1 clinical studies of MT-601, its multi-antigen recognizing T cell therapy, in locally advanced unresectable pancreatic cancer. The award represents competitive recognition of the company's MAR-T platform, which has shown a disease control rate of 84.6% in earlier studies. Clinical initiation is anticipated in Q1 2027.
Marker Therapeutics (MRKR) has been upgraded to a Zacks Rank #1 (Strong Buy) rating due to rising earnings estimates. The company's consensus estimate has increased 45.3% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects an improving business outlook that could drive near-term stock price appreciation.
Zacks has added five stocks to its Strong Buy list based on increasing consensus earnings estimates over the last 60 days. The stocks span energy, technology distribution, immuno-oncology, biopharmaceutical, and chemical manufacturing sectors, with earnings estimate increases ranging from 3.5% to 30.6%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.